What were the key takeaways from HCA Healthcare's earnings call?

What does HCA Healthcare do and what are its main business segments?

What is the market's earnings forecast for HCA Healthcare next quarter?

What guidance did HCA Healthcare's management provide for the next earnings period?

What is HCA Healthcare's gross profit margin?

Did HCA Healthcare beat or miss consensus estimates last quarter?

What factors drove the changes in HCA Healthcare's revenue and profit?

What were the key takeaways from HCA Healthcare’s earnings call?

- **Revenue and Profit Growth**: 6.7% revenue increase, 11% EBITDA growth, 29% EPS rise in 2025. 2026 guidance for flat to higher margins despite $600-$900M headwinds.
- **Resiliency Program**: $400M savings to offset exchange reforms, including digital transformation and shared services.
- **Capital Allocation**: $2.6B share buybacks, $1.5B capex in 2025. 2026 capex raised to $5-$5.5B for outpatient expansion.
- **Policy Risks**: 15%-20% exchange volume decline, 30% utilization drop for uninsured, Texas supplemental payments paused.
- **AI and Digital Transformation**: $400M savings from AI, EHR transition, and clinical insights. 2026 focus on operational efficiency and patient access.

**【CEO Summary Section】**
- **Revenue Growth**: 6.7% year-over-year, driven by strong demand and network expansion. Adjusted EBITDA increased 11%, and diluted EPS rose 29%.
- **Resiliency Program**: $400 million savings to offset $600-$900 million headwinds from exchange reforms and EPTC expiration. Includes cost efficiencies, digital transformation, and shared services.
- **Investments**: $1.5 billion in capital expenditures, $2.6 billion in share buybacks, and $162 million in dividends. 2026 capital budget raised to $5-$5.5 billion for outpatient and inpatient capacity.

**【CFO Financial Commentary】**
- **2025 Results**: Revenue $76.5-$80 billion, adjusted EBITDA $15.55-$16.4 billion, net income $6.5-$7 billion. 2026 guidance reflects 2%-3% volume growth, $250-$450 million decline in supplemental payments, and $400 million resiliency savings.
- **Margins**: 2025 adjusted EBITDA margin improved 90 basis points. 2026 guidance for flat to slightly higher margins despite headwinds.
- **Policy Impact**: 15%-20% decline in exchange volumes, 30% drop in utilization for uninsured. Texas supplemental payments paused, Tennessee program reduced to 4 quarters of benefit.

**【Q&A Highlights】**
- **Medicaid Changes**: 2.2% growth in Medicaid admissions, stable payer mix. Virginia retro payment offset $420 million net benefit from supplements.
- **AI and Digital Transformation**: $400 million resiliency savings include AI-driven cost efficiencies, digital claims processing, and shared service platforms. 2026 focus on EHR transition and clinical insights.
- **Margin Sustainability**: Confidence in maintaining >20% margin through resiliency, volume growth, and cost control. 2026 guidance assumes 2%-3% volume growth, 15%-20% exchange volume decline, and 30% utilization drop for uninsured.

HCA Healthcare, Inc.(HCA)-20260127-2025 Q4 Earnings call transcript

- **Revenue Growth**: 9.6% Q3 revenue increase, driven by volume and Medicaid supplements, with 42% EPS growth.
- **Margin Expansion**: Adjusted EBITDA margin improved due to cost control and Medicaid programs ($240M Q3 benefit).
- **2025 Guidance**: EPS raised to $27-$28, with $250M-$350M Medicaid supplement net benefit.
- **2026 Outlook**: 2-3% volume growth expected, with cautious federal policy outlook.
- **AI and Efficiency**: Piloting AI tools for documentation and revenue cycle, with strong cash flow conversion (>50%).

**【CEO Summary Section】**
- **Strong Q3 Results**: Diluted EPS grew 42% YoY, driven by 9.6% revenue increase from volume growth, improved payer mix, and Medicaid supplemental programs. Adjusted EBITDA margin expanded due to cost control.
- **Resiliency Plan Progress**: Teams executed on operational efficiency, digital tools, and capacity expansion, with a focus on 2026 demand outlook of 2-3% volume growth and stable cost trends.
- **Federal Policy Impact**: Advocacy for premium tax credit extensions continues amid uncertainty, with potential impacts on 2026 volumes and costs.

**【CFO Financial Commentary】**
- **Revenue Growth Drivers**: Same-facility admissions up 2.4%, surgical volumes stable, and net revenue per admission boosted by Medicaid supplements ($240M Q3 benefit). Exchange and Medicare growth offset self-pay decline.
- **Expense Management**: Operating expenses controlled, with contract labor flat YoY. Medicaid supplements added $250M-$350M full-year EBITDA benefit, excluding pending state approvals.
- **Capital Allocation**: $2.5B share buybacks and $1.3B capex, with strong cash flow ($4.4B Q3) supporting balance sheet strength.
- **Guidance Update**: Full-year 2025 EPS raised to $27-$28, reflecting operational performance and Medicaid supplements. 2026 outlook cautious on federal policy but confident in 2-3% volume growth.

**【Q&A Highlights】**
- **Medicaid Supplements**: Tennessee, Texas, and Kansas approvals drove Q3 benefits, with potential $250M-$350M 2025 net gain. Florida, Georgia, and Virginia grandfathered programs pending CMS review.
- **Hurricane Recovery**: 2025 EBITDA expected to recover $100M of 2024's $250M hurricane impact, with lingering North Carolina costs.
- **AI Adoption**: Ambient AI tools for clinical documentation and revenue cycle automation are piloting, with focus on denial management.
- **Cash Flow Conversion**: Strong working capital management and deferred taxes drove 50%+ EBITDA-to-free cash flow, sustainable with disciplined operations.


HCA Healthcare, Inc. (HCA) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 6.4% YoY to $18.5B, driven by demand and payer mix improvements.
- **Margin Expansion**: EBITDA margin +30bps to 19.1%, supported by cost control and hurricane recovery.
- **Guidance Update**: Raised 2025 EPS to $25.50-27, reflecting $100M Medicaid program benefit and operational improvements.
- **Resiliency Strategy**: $600-800M savings over 5 years via automation, digital tools, and shared services.
- **Risk Mitigation**: 60% Medicaid in non-expansion states; resiliency programs targeting 2026 EPTC expiration impact.

**【CEO Summary Section】**
- Q2 2025 revenue grew 6.4% YoY to $18.5 billion, driven by demand recovery, improved payer mix, and stable patient acuity.
- Adjusted EPS increased 24% YoY to $6.84, with $100 million net benefit from state supplemental Medicaid programs.
- Raised 2025 guidance: Revenue $74-76B, EPS $25.50-27, EBITDA $14.7-15.3B.
- Federal policy risks (One Big Beautiful Bill Act) expected to be manageable, with 60% of Medicaid volumes in non-expansion states.
- Hurricane-impacted markets (FL, NC) outperformed expectations, contributing $100M to guidance update.

**【CFO Financial Commentary】**
- Equivalent admissions +1.7% QoQ, +2.3% YoY; managed care +4%, Medicare +3%, Medicaid -1.2%.
- Adjusted EBITDA margin +30bps YoY to 19.1%, driven by cost control (salary/benefits -1.2% of revenue, supply costs +1.3%).
- Capital allocation: $1.2B share buybacks, $850M deferred taxes, $5B 2025 capex.
- Resiliency programs targeting $600-800M savings over 5 years via automation, digital transformation, and shared services.

**【Q&A Key Highlights】**
- **Volume Trends**: Medicaid and self-pay underperformance (-1.2% and +1.5% YoY) offset Medicare (+3%) and commercial (+4%) growth.
- **Resiliency Programs**: Focus on length of stay, case management, and labor automation to offset potential EPTC expiration impact.
- **Market Share**: 14/15 divisions achieved admission growth; 58% of Medicare in Advantage plans with stable denial rates.
- **Hurricane Recovery**: FL and NC markets expected to fully recover by Q4, with $100M EBITDA benefit vs. flat prior guidance.
- **Policy Risks**: 60% of Medicaid in non-expansion states; resiliency programs aim to offset 2026 exchange provisions impact.

HCA Healthcare (HCA)-25 Jul 25-2025 Q2 Earnings call transcript

- **Revenue Growth & Margin Expansion**: 15% YoY revenue growth, 20% EPS increase, 110bps EBITDA margin expansion.
- **Operational Efficiency**: Salaries +80bps, supplies +30bps, contract labor utilization down to 4.4%.
- **Capital Allocation**: $2.5B share buybacks, $5.2B capex, and $161M asset sales.
- **Policy Risk Management**: 70% 2025 supply contracts fixed-priced; 75% supply chain from low-tariff regions.
- **Surgical Mix**: Outpatient volumes down 2.1% YoY, but net revenue growth due to acuity shift.
- **Labor Market Stability**: Turnover rates stable, wage inflation guidance unchanged.
- **Digital Transformation**: AI and automation initiatives in clinical, operational, and administrative functions.


**【CEO Summary Section】**
- Q1 2025 revenue grew 15% YoY, driven by volume growth (inpatient admissions +2.6%, ER visits +4%), improved payer mix, and operating margin expansion.
- Adjusted EPS increased 20% YoY to $6.45, with same-facility revenue up 6% due to volume and pricing improvements.
- Capital spending focused on network expansion (3.3% new sites, 2% inpatient bed capacity), maintaining 77% inpatient occupancy.
- Management emphasized navigating federal policy uncertainty with financial strength and operational flexibility.

**【CFO Financial Commentary】**
- GAAP net income: $420 million; Non-GAAP EPS: $1.08 (vs. $0.95 prior year).
- Adjusted EBITDA margin improved 110bps to 17.3%, driven by cost control (salaries +80bps, supplies +30bps) and operating leverage.
- Capital allocation: $991M in capex, $2.5B share buybacks, $180M dividends, and $161M from asset sales.
- Medicaid state supplemental payments net benefit increased $18M YoY, offsetting policy risks.

**【Q&A Key Themes】**
1. **Surgical Volume Mix**: Outpatient surgery volumes down 2.1% YoY (leap year-adjusted -1%), but net revenue growth due to higher acuity cases. Inpatient surgeries slightly up on a per-business-day basis.
2. **Policy Risks**: Tariff impact on 70% of 2025 supply contracts fixed-priced; 75% of supply chain from US/Canada/Mexico or pharmaceuticals. No tariff impact estimated for 2025.
3. **Labor Market**: Turnover rates stable, contract labor utilization down to 4.4% of total labor costs. Wage inflation guidance unchanged despite macro uncertainty.
4. **CapEx & Share Buybacks**: $5.2B capex target for 2025; $10B share buyback authorization, with $2.5B executed in Q1.
5. **Managed Care Contracts**: Over 90% of 2025 contracts signed, 75% for 2026, with improved access to commercial and exchange lives.
6. **Medicare Advantage**: 57% of Medicare admissions via MA plans, with higher observation stays and length of stay compared to traditional Medicare.
7. **Technology Investment**: Digital transformation group advancing AI and automation in clinical, operational, and administrative functions.
8. **Tariff Preparedness**: HealthTrust securing fixed pricing, diversifying suppliers away from China, and maintaining 2025 tariff risk as manageable.
9. **Flu Impact**: Respiratory volumes in line with prior year, no material impact on patient receivables or collections.
10. **Market Share**: Gains across cardiac, rehab, and inpatient services; behavioral health volumes down due to intentional bed repurposing.


HCA Healthcare (HCA)-25 Apr 25-2025 Q1 Earnings call transcript

- **Resilient Q4 growth**: 6% revenue expansion, 3% admissions growth, and $24.05-$25.85 EPS guidance despite $200M hurricane costs.
- **2025 outlook**: 3%-4% admissions growth, flat to -$250M Medicaid headwind, and 10.75B-$11.25B cash flow.
- **Balance sheet strength**: $10B buyback authorization, 12% dividend hike, and 2.75-3.75x leverage target.
- **Operational excellence**: 10bps EBITDA margin improvement, 8% reduction in contract labor, and 124 ASCs driving outpatient growth.


**【CEO Summary Section】**
- **Strong operational performance**: FY2024 revenue growth driven by 6% top-line expansion, with same-facility admissions up 3% and ER visits increasing 2.4%. Hurricane impacts were effectively managed, with facilities fully operational by Q4.
- **Long-term growth momentum**: 10-year EBITDA margin improvement, capital allocation focused on network expansion (e.g., 124 ASCs) and shareholder returns ($6B+ in buybacks and dividends in 2024).
- **2025 outlook**: Guidance for $72.8B-$75.8B revenue, 3%-4% equivalent admissions growth, and flat to +$250M headwind from Medicaid supplemental programs.

**【CFO Financial Commentary】**
- **Q4 2024 results**: Adjusted EPS up 5.4% YoY to $24.05-$25.85, with $200M hurricane-related costs offsetting 6% revenue growth. Full-year EBITDA margin improved 10bps to 14.3%, despite $250M hurricane impact.
- **Capital discipline**: 2024 operating cash flow of $10.5B (11% YoY growth), with $5.1B 2025 CapEx targeting network expansion and efficiency (e.g., OR/ER optimization).
- **Balance sheet strength**: Lowered leverage target to 2.75-3.75x, enabling $10B share buyback authorization and 12% dividend increase.

**【Key Q&A Themes】**
- **Medicaid dynamics**: 2024 supplemental program net benefit of $400M, with 2025 guidance of flat to -$250M headwind. Medicaid admissions down 10% Q4, offset by commercial/exchange growth.
- **Labor market**: Contract labor down 8% YoY to 4.5% of SWD, with focus on retention (nurse turnover <10%) and workforce development (15k+ Galen graduates).
- **Policy risks**: Tariff mitigation strategies in place, with 70% of 2025 supplies under fixed-price contracts. No material impact expected from immigration policies.


Actual																2.33	3.23	1.92	4.13	4.14	4.37	4.57	4.42	4.12	4.21	3.93	4.64	4.93	4.29	3.91	5.9	5.36	5.5	4.9	6.22	6.45	6.84	6.96	8.01
Forecast																2.638	-0.1944	2.294	3.5674	3.3248	3.1627	4.062	4.5158	4.2622	3.6995	3.8804	4.7902	3.9122	4.2467	3.9753	5.0476	5.056	4.9331	4.9577	6.1303	5.7494	6.2936	5.792	7.46	7.1663
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-11.68%	+1761.52%	-16.30%	+15.77%	+24.52%	+38.17%	+12.51%	-2.12%	-3.34%	+13.80%	+1.28%	-3.14%	+26.02%	+1.02%	-1.64%	+16.89%	+6.01%	+11.49%	-1.16%	+1.46%	+12.19%	+8.68%	+20.17%	+7.37%	0.00%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	12.86B	11.07B	13.31B	14.29B	13.98B	14.44B	15.28B	15.06B	14.95B	14.82B	14.97B	15.50B	15.59B	15.86B	16.21B	17.30B	17.34B	17.49B	17.49B	18.29B	18.32B	18.61B	19.16B	19.51B	--
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	13.06B	10.09B	12.85B	13.99B	13.63B	13.61B	14.53B	15.35B	14.75B	14.72B	15.00B	15.63B	15.27B	15.63B	15.82B	16.51B	16.81B	17.05B	17.54B	18.23B	18.26B	18.50B	18.60B	19.67B	19.09B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.56%	+9.68%	+3.62%	+2.18%	+2.53%	+6.05%	+5.10%	-1.87%	+1.33%	+0.65%	-0.20%	-0.85%	+2.12%	+1.47%	+2.47%	+4.79%	+3.14%	+2.57%	-0.30%	+0.28%	+0.34%	+0.57%	+3.02%	-0.82%	0.00%

HCA

HCA fundamentals

HCA Q1 2026 Earnings Preview

Earnings Call

You can ask Aime

HCA

HCA fundamentals

HCA Q1 2026 Earnings Preview

Earnings Call

HCA Earnings Call Summary for Q1/2026Upcoming10:00 AM on Apr 24, 2026

HCA Earnings Call Summary for Q4/202510:00 AM on Jan 27, 2026

HCA Earnings Call Summary for Q3/202510:00 AM on Oct 24, 2025

HCA Earnings Call Summary for Q2/202510:00 AM on Jul 25, 2025

HCA Earnings Call Summary for Q1/202510:00 AM on Apr 25, 2025

You can ask Aime